This brand name is authorized in Estonia
The drug LEDIPIN contains one active pharmaceutical ingredient (API):
|
1
Lercanidipine
UNII V7XTJ4R0BH - LERCANIDIPINE
|
|
Lercanidipine is a calcium antagonist of the dihydropyridine group and inhibits the transmembrane influx of calcium into cardiac and smooth muscle. The mechanism of its antihypertensive action is due to a direct relaxant effect on vascular smooth muscle thus lowering total peripheral resistance. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C08CA13 | Lercanidipine | C Cardiovascular system → C08 Calcium channel blockers → C08C Selective calcium channel blockers with mainly vascular effects → C08CA Dihydropyridine derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1371271, 1371282, 1371293, 1371305, 1371316, 1371327, 1371338, 1371361, 1371372, 1371383, 1371394, 1371406, 1371417, 1371428 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
